Systemic inflammatory responses to surgery with cardiopulmonary bypass

Abstract

Get full access to this article

View all access options for this article.

References

Edmunds L. Jr.Blood-surface interactions during cardiopulmonary bypass. J Cardiac Surg 1993; 8: 404-10.

Royston D. Blood cell activation. Semin Thorac Cardiovasc Surg 1990; 2: 341-57.

Royston D. , Minty B. , Wallwork J. , Higenbottam T. , Jones J. The effects of surgery with cardiopulmonary bypass on alveolar-capillary barrier function in man. Ann Thorac Surg 1985 ; 40: 133-42.

Tsiotos GG , Mullany CJ , Zietlow S. , van-Heerden JA Abdominal complications following cardiac surgery. Am J Surg 1994; 167: 553-57.

Nussmeier NA Neuropsychiatric complications of cardiac surgery . J Cardiothorac Vasc Anesth 1994; 8: 13-18.

Hennein HA , Ebba H. , Rodriguez JL et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108: 626-35.

Iwanaga S. , Muta T. , Shigenaga T. et al. Role of hemocyte-derived granular components in invertebrate defense. Ann NY Acad Sci 1994; 712: 102-16.

Muta T. , Oda T. , Iwanaga S. Horseshoe crab coagulation factor B. A unique serine protease zymogen activated by cleavage of an Ile-Ile bond. J Biol Chem 1993; 268: 21384-88.

Muta T. , Tokunaga F. , Nakamura T. , Morita T. , Iwanaga S. Limulus clotting factor C: lipopolysaccharide-sensitive serine protease zymogen . Methods Enzymol 1993; 223: 336-45.

10.

Tapparelli C. , Metternich R. , Ehrhardt C. , Cook NS Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993; 14: 366-76.

11.

Fareed J. , Hoppensteadt D. , Walenga JM , Bick RL Current trends in the development of anticoagulant and antithrombotic drugs . Med Clin North Am 1994; 78: 713-31.

12.

Colman RW , Mattler L. , Sherry S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest 1969; 48: 23-32.

13.

Colman RW , Mattler L. , Sherry S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. I. Isolation of purification of plasma kallikreins. J. Clin Invest 1969; 48: 11-22.

14.

Wachtfogel YT , Kucich U. , Hack CE et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion . J Thorac Cardiovasc Surg 1993; 106: 1-9.

15.

Wiggins RC , Giclas PC , Henson PM Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 1981; 153: 1391-404.

16.

Ward PA A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med 1967, 126: 189-206, Issn: 0022-1007.

17.

Boisclair MD , Lane DA , Philippou H. et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-57.

18.

Burman JF , Chung HI , Lane DA , Philippou H. , Adami A. , Lincoln Jcr. Role of Factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 1994; 344: 1192-93.

19.

Chenoweth DE , Cooper SW , Hugli TE , Stewart RW , Blackstone EH , Kirklin JW Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins . N Engl J Med 1981; 304: 497-503.

20.

Kirklin JK , Westaby S. , Blackstone EH , Kirklin JW , Chenoweth DE , Pacifico AD Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845-57.

21.

Westaby S. Complement and the damaging effects of cardiopulmonary bypass [editorial] . Thorax 1983; 38: 321-25.

22.

Weinberg PF , Matthay MA , Weslen O. , Roskos KV , Godstein TM , Murray JF Biologically active products of complement and acute lung injury in patients with the sepsis syndrome . Am Rev Respir Dis 1984; 130: 791-96.

23.

Gillinov AM , Redmond JM , Winkelstein JA et al. Complement and neutrophil activation during cardiopulmonary bypass: a study in the complement-deficient dog. Ann Thorac Surg 1994; 57: 345-52.

24.

Homeister JW , Satoh P. , Lucchesi BR Effects of complement activation in the isolated heart. Role of the terminal complement components . Circ Res 1992; 71: 303-19.

25.

Utley JR Pathophysiology of cardiopulmonary bypass: current issues. J Cardiac Surg 1990; 5: 177-89.

26.

Sundaram S. , Courtney JM , Taggart DP et al. Biocompatibility of cardiopulmonary bypass: influence on blood compatibility of device type, mode of blood flow and duration of application . Int J Artif Organs 1994; 17: 118-28.

27.

Nilsson L. , Tyden H. , Johansson O. et al. Bubble and membrane oxygenators-comparison of postoperative organ dysfunction with special reference to inflammatory activity. Scand J Thorac Cardiovasc Surg 1990; 24: 59-64.

28.

Salzman EW , Merrill EW , Binder A. , Wolf CF , Ashford TP , Austen WG Protein-platelet interaction on heparinized surfaces. J Biomed Mater Res 1969; 3: 69-81.

29.

Gluszko P. , Rucinski B. , Musial J. et al. Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. Am J Physiol 1987; 252: H615-21.

30.

Musial J. , Niewiarowski S. , Hershock D. , Morinelli TA , Colman RW , Edmunds LH Jr.Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. J Lab Clin Med 1985; 105: 514-22.

31.

Harker LA Bleeding after cardiopulmonary bypass [Editorial]. N Engl J Med 1986; 314: 1446-48.

32.

Zilla P. , Fasol R. , Groscurth P. , Klepetko W. , Reichenspurner H. , Wolner E. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 1989; 97: 379-88.

33.

Fidlar E. , Jaques L. The effects of commercial heparin on the platelet count. J Lab Clin Med 1948; 33: 1410.

34.

Warkentin TE , Kelton JG Heparin and platelets. Hematol Oncol Clin North Am 1990; 4: 243-64.

35.

Fish KJ , Sarnquist FH , van Steennis C. et al. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg 1986; 91: 436-42.

36.

Davis R. , Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995; 49: 954-83.

37.

Murase M. , Usui A. , Tomita Y. , Maeda M. , Koyama T. , Abe T. Nafamostat mesylate reduces blood loss during open heart surgery. Circulation 1993; 88: 432-36.

38.

Royston D. High-dose aprotinin therapy: a review of the first five years' experience . J Cardiothorac Vasc Anesth 1992; 6: 76-100.

39.

Wildevuur CR , Eijsman L. , Roozendaal KJ , Harder MP , Chang M. , van Oeveren W. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989; 3: 533-37.

40.

Lu H. , Soria C. , Soria J. et al. Reversible translocation of glycoprotein Ib in plasmin-treated platelets: consequences for platelet function. Eur J Clin Invest 1993; 23: 785-93.

41.

Orchard MA , Goodchild CS Prentice CR et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85: 533-41.

42.

Ketterl R. , Haas S. , Lechner F. , Kienzle H. , Blumel G. [Effect of aprotinin on thrombocytic function during total endoprosthesis surgery of the hip]. Med Welt 1980; 31: 1239-43.

43.

Ketterl R. , Haas S. , Heiss A. et al. [Effect of the natural proteinase inhibitor aprotinin on platelet function in allo-arthroplastic hip replacement]. Med Welt 1982; 33: 480-86.

44.

Haas S. , Ketterl R. , Stemberger A. et al. The effect of aprotinin on platelet function, blood coagulation and blood lactate level in total hip replacement - a double blind clinical trial. Adv Exp Med Biol 1984; 167: 287-97.

45.

Haas S. , Müller-Esterl W. , Fritsche H-M. et al. Effect of aprotinin on the incidence of thrombosis and postoperative bleeding. Thromb Haemostasis 1985; 54: 587: Abstract 99.

46.

Royston BD , Royston D. , Pearson JD Aprotinin inhibits platelet adhesion to endothelial cells. Blood Coagul Fibrinolysis 1992; 3: 737-42.

47.

Royston BD , Royston D. , Coade SB , Morgan DM , Pearson JD Aprotinin does not inhibit the release of PGI2 or vWF from cultured human endothelial cells. Thromb Haemost 1992 ; 67: 172-75.

48.

Soslau G. , Horrow J. , Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation . Am J Hematol 1991; 38: 113-19.

49.

Boldt J. , Schindler E. , Osmer C. , Wittstock M. , Stertmann WA , Hempelmann G. Influence of different anticoagulation regimens on platelet function during cardiac surgery. Br J Anaesth 1994; 73: 639-44.

50.

Lu H. , Soria C. , Commin PL et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-37.

51.

Lazenby WD , Russo I. , Zadeh BJ et al. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation 1990; 82: IV413-19.

52.

Andersson TL , Solem JO , Tengborn L. , Vinge E. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation 1990 ; 81: 872-78.

53.

Blauhut B. , Gross C. , Necek S. , Doran JE , Spath P. , Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-67.

54.

Blauhut B. , Harringer W. , Bettelheim P. , Doran JE , Spath P. , Lundsgaard Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 1083-91, Issn: 0022-5223.

55.

Freise J. , Witenberg H. , Magerstedt P. In vitro inhibition of phospholipase A2 by gabexate mesilate, camostate, and aprotinine. Klin Wochenschr 1989; 67: 149-52.

56.

Nagaoka H. , Innami R. , Murayama F. et al. Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg Torino 1991; 32: 31-37.

57.

Gillinov AM , Bator JM , Zehr KJ et al. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 1993; 56: 847-53.

58.

Royston D. , Fleming JS , Desai JB , Westaby S. , Taylor KM Increased production of peroxidation products associated with cardiac operations. Evidence for free radical generation. J Thorac Cardiovasc Surg 1986; 91: 759-66.

59.

Menasche P. , Piwnica A. Free radicals and myocardial protection: a surgical viewpoint. Ann Thorac Surg 1989 ; 47: 939-45.

60.

Menasche P. , Antebi H. , Alcindor LG et al. Iron chelation by deferoxamine inhibits lipid peroxidation during cardiopulmonary bypass in humans. Circulation 1990; 82: IV390-96.

61.

Fuhrer G. , Gallimore MJ , Heller W. , Hoffmeister HE Aprotinin in cardiopulmonary bypass-effects on the Hageman factor (FXII)-Kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992; 3: 99-104.

62.

Heller W. , Fuhrer G. , Gallimore MJ , Michel J. , Hoffmeister HE Changes in the kallikrein-kinin-system after different dose regimen of aprotinin during cardiopulmonary bypass operation. Adv Exp Med Biol 1989; 247b: 43-48.

63.

Faymonville ME , Pincemail J. , Duchateau J. et al. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1991; 102: 309-17.

64.

Mair P. , Mair J. , Seibt I. , Furtwaengler W. , Balogh D. , Puschendorf B. Plasma elastase concentrations and pulmonary function after cardiopulmonary bypass [Letter]. J Thorac Cardiovasc Surg 1994; 108: 184-85.

65.

Steinberg JB , Kapelanski DP , Olson Jhd , Weiler JM Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106:P 1008-16.

66.

Haeffner-Cavaillon N. , Roussellier N. , Ponzio O. et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 98: 1100-106.

67.

Stahl RF , Fisher CA , Kucich U. et al. Effects of simulated extracorporeal circulation on human leukocyte elastase release, superoxide generation, and procoagulant activity. J Thorac Cardiovasc Surg 1991; 101: 230-39.

68.

Gurevitch J. , Paz Y. , Barak J. et al. Role of protease inhibition in myocardial preservation following ischemia and reperfusion. J Cardiovasc Surg Torino 1994; 35: 95-98.

69.

Sunamori M. , Innami R. , Amano J. , Suzuki A. , Harrison CE Role of protease inhibition in myocardial preservation in prolonged hypothermic cardioplegia followed by reperfusion. Effect of aprotinin in an experimental model. J Thorac Cardiovasc Surg 1988; 96: 314-20.

70.

Coghlan JG , Flitter WD Clutton SM et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting . J Thorac Cardiovasc Surg 1994; 107: 248-56.

71.

Welbourn R. , Goldman G. , O'Riordain M. et al. Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia . J Appl Physiol 1991; 70: 2645-49.

72.

Welbourn CR , Goldman G. , Paterson IS , Valeri CR , Shepro D. , Hechtman HB Neutrophil elastase and oxygen radicals: synergism in lung injury after hindlimb ischemia. Am J Physiol 1991; 260: H1852-56.

73.

Lindsay TF , Hill J. , Ortiz F. et al. Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion. Ann Surg 1992; 216: 677-83.

74.

Gadaleta D. , Fantini GA , Silane MF , Davis JM Leukotriene generation and pulmonary dysfunction following aortic cross clamp in humans. Ann NY Acad Sci 1994; 723: 470-72.

75.

Muylle L. , Joos M. , Wouters E. , De Bock R. , Peetermans ME Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions . Transfusion 1993; 33: 195-99.

76.

Muylle L. , Peetermans ME Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 66: 14-17.

77.

Stack G. , Snyder EL Cytokine generation in stored platelet concentrates. Transfusion 1994; 34: 20-25.

78.

Connall TP , Zhang J. , Vaziri ND , Kaupke CJ , Wilson SE Leukocyte CD11b and CD18 expression are increased in blood salvaged for autotransfusion . Am Surg 1994; 60: 797-800.

79.

Arnestad JP , Bengtsson A. , Bengtson JP , Tylman M. , Redl H. , Schlag G. Formation of cytokines by retransfusion of shed whole blood. Br J Anaesth 1994; 72: 422-25.

80.

de Haan J. , Boonstra PW , Monnink SH , Ebels T. , van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis . Ann Thorac Surg 1995; 59: 901-907.

81.

Hannes W. , Keilich M. , Koster W. , Seitelberger R. , Fasol R. Shed blood autotransfusion influences ischemia-sensitive laboratory parameters after coronary operations. Ann Thorac Surg 1994; 57: 1289-94.